Retrophin to Report Third Quarter 2020 Financial Results
Retrophin, Inc. (NASDAQ: RTRX) will report its third quarter 2020 financial results on November 5, 2020, after U.S. market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Retrophin, Inc. (NASDAQ: RTRX) will report its third quarter 2020 financial results on November 5, 2020, after U.S. market close. A conference call is scheduled for 4:30 p.m. ET to discuss these results and provide a business update. Interested parties can join via a live webcast on Retrophin's website. A replay will be available from November 5 to November 12, 2020. Retrophin focuses on developing therapies for rare diseases, with key products and ongoing research initiatives in nephrology, supported by revenues from existing commercial products.
Positive
- Anticipated financial results and business update could indicate company growth.
- Strong focus on rare disease therapies, particularly in late-stage development.
Negative
- None.
Details
News Market Reaction – RTRX
The recorded move for RTRX in the trading session of this news was +2.28%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report third quarter 2020 financial results on Thursday, November 5, 2020 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
| Conference Call Information | |
| Date: | Thursday, November 5, 2020 |
| Time: | 4:30 p.m. ET |
| Dial-in numbers: | +1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International) |
| Confirmation code: | 7362327 |
| Live webcast: | Retrophin.com in the “Events & Presentations” section of the “Investors” page |
A replay of the call will be available from 7:30 p.m. ET, November 5, 2020 to 7:30 p.m. ET, November 12, 2020. The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International), confirmation code 7362327.
About Retrophin
Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease. The Company’s approach centers on its pipeline featuring sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), rare disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including partnerships with leaders in patient advocacy and government research to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, conditions with no approved treatment options. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal®, Cholbam®, Thiola® and Thiola EC®.
Contact:
Chris Cline, CFA
Senior Vice President, Investor Relations & Corporate Communications
888-969-7879
IR@retrophin.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.